Avenue Therapeutics ATXI Stock
4.79 USD
{{ price }}
-4.391222%
{{change_pct}}%
SECTOR
Healthcare
INDUSTRY
Biotechnology
COUNTRY
United States
Exchange
NasdaqCM
Market Cap
6M USD
LOW - HIGH [24H]
0.14
-
0.14 USD
VOLUME [24H]
22.64K USD
{{ volume }}
P/E Ratio
0
Earnings per share
-0.98 USD
Avenue Therapeutics Price Chart
Avenue Therapeutics ATXI Financial and Trading Overview
| Avenue Therapeutics stock price | 4.79 USD |
| Previous Close | 1.13 USD |
| Open | 1.13 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 900 |
| Day's Range | 1.08 - 1.17 USD |
| 52 Week Range | 0.87 - 16.65 USD |
| Volume | 52.65K USD |
| Avg. Volume | 255.59K USD |
| Market Cap | 9.19M USD |
| Beta (5Y Monthly) | -0.448943 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.98 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 32 USD |
ATXI Valuation Measures
| Enterprise Value | 246.76K USD |
| Trailing P/E | N/A |
| Forward P/E | -0.5471698 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Avenue Therapeutics Stock Price History
| Beta (5Y Monthly) | -0.448943 |
| 52-Week Change | -69.066% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 16.65 USD |
| 52 Week Low | 0.87 USD |
| 50-Day Moving Average | 1.08 USD |
| 200-Day Moving Average | 1.95 USD |
ATXI Share Statistics
| Avg. Volume (3 month) | 255.59K USD |
| Avg. Daily Volume (10-Days) | 74.85K USD |
| Shares Outstanding | 7.92M |
| Float | 6.46M |
| Short Ratio | 2.37 |
| % Held by Insiders | 15.69% |
| % Held by Institutions | 11.94% |
| Shares Short | 195.5K |
| Short % of Float | 2.75% |
| Short % of Shares Outstanding | 2.46% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:15 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -139.49% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -8227000 USD |
| Diluted EPS (ttm) | -2.9 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 8.24M USD |
| Total Cash Per Share (mrq) | 1.04 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.797 |
| Book Value Per Share (mrq) | -0.213 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -7239000 USD |
| Levered Free Cash Flow (ttm) | 2.55M USD |
Profile of Avenue Therapeutics
| Country | United States |
| State | FL |
| City | Tampa |
| Address | 1111 Kane Concourse |
| ZIP | 33154 |
| Phone | 781 652 4500 |
| Website | https://www.avenuetx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 2 |
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product candidate includes AJ201, which in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous (IV) Tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. Avenue Therapeutics, Inc. was incorporated in 2015 and is based in Tampa, Florida.
Q&A For Avenue Therapeutics Stock
What is a current ATXI stock price?
Avenue Therapeutics ATXI stock price today per share is 4.79 USD.
How to purchase Avenue Therapeutics stock?
You can buy ATXI shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Avenue Therapeutics?
The stock symbol or ticker of Avenue Therapeutics is ATXI.
Which industry does the Avenue Therapeutics company belong to?
The Avenue Therapeutics industry is Biotechnology.
How many shares does Avenue Therapeutics have in circulation?
The max supply of Avenue Therapeutics shares is 1.25M.
What is Avenue Therapeutics Price to Earnings Ratio (PE Ratio)?
Avenue Therapeutics PE Ratio is now.
What was Avenue Therapeutics earnings per share over the trailing 12 months (TTM)?
Avenue Therapeutics EPS is -0.98 USD over the trailing 12 months.
Which sector does the Avenue Therapeutics company belong to?
The Avenue Therapeutics sector is Healthcare.
Avenue Therapeutics ATXI included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Capital Market Composite RCMP | 114.55 USD — |
-2.27
|
— — | 114.09 USD — | 116.72 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}